FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:694-701 February 20, 2003 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Wittes, R. E. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults. A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after standard therapy. We designed a study to test whether the addition of these drugs to a standard regimen would improve the survival of patients with newly diagnosed disease.

Methods Patients 30 years old or younger with Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone were eligible. The patients were randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating with courses of ifosfamide and etoposide.

Results A total of 518 patients met the eligibility requirements. Of 120 patients with metastatic disease, 62 were randomly assigned to the standard-therapy group and 58 to the experimental-therapy group. There was no significant difference in five-year event-free survival between the treatment groups (P=0.81). Among the 398 patients with nonmetastatic disease, the mean (±SE) five-year event-free survival among the 198 patients in the experimental-therapy group was 69±3 percent, as compared with 54±4 percent among the 200 patients in the standard-therapy group (P=0.005). Overall survival was also significantly better among patients in the experimental-therapy group (72±3.4 percent vs. 61±3.6 percent in the standard-therapy group, P=0.01).

Conclusions The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.

Source Information

From the Departments of Pediatric Hematology and Oncology, Dana–Farber Cancer Institute and Children's Hospital, Boston (H.E.G.); Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (M.D.K.); Radiation Oncology, Massachusetts General Hospital, Boston (N.J.T.); Pediatrics (H.E.G.), Radiation Oncology (N.J.T.), and Orthopedic Surgery (M.C.G.), Harvard Medical School, Boston; Pediatrics (M.P.L.) and Radiation Oncology (S.S.D.), Stanford University School of Medicine, Stanford, Calif.; Pediatrics, King Khalid National Hospital, Jeddah, Saudi Arabia (C.J.H.F.); the Mayo Clinic, Rochester, Minn. (D.J.P.); Orthopedic Surgery, Children's Hospital, Boston (M.C.G.); Pathology, Children's Hospital of Pittsburgh, Pittsburgh (P.S.D.); Pathology, Johns Hopkins Hospital, Baltimore (E.J.P.); Memorial Sloan-Kettering Cancer Center, New York (P.A.M.); Keck School of Medicine, University of Southern California, and Radiology, Children's Hospital of Los Angeles — both in Los Angeles (S.M.); Pediatrics, New York University Medical Center, New York (A.R.R.); the Division of Pediatric Hematology and Oncology, Washington University Medical Center, and Pediatrics, Washington University School of Medicine, St. Louis (T.J.V.); and Pediatrics, City of Hope National Medical Center, Duarte, Calif. (J.S.M.).

Address reprint requests to Dr. Grier at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115, or at holcombe_grier{at}dfci.harvard.edu.

Full Text of this Article

This article has been cited by other articles:

• Arndt, C. A.S., Stoner, J. A., Hawkins, D. S., Rodeberg, D. A., Hayes-Jordan, A. A., Paidas, C. N., Parham, D. M., Teot, L. A., Wharam, M. D., Breneman, J. C., Donaldson, S. S., Anderson, J. R., Meyer, W. H. (2009). Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. JCO 27: 5182-5188 [Abstract] [Full Text]  
• Sewell, M. D., Spiegelberg, B. G. I., Hanna, S. A., Aston, W. J. S., Bartlett, W., Blunn, G. W., David, L. A., Cannon, S. R., Briggs, T. W. R. (2009). Total femoral endoprosthetic replacement following excision of bone tumours. J Bone Joint Surg Br 91-B: 1513-1520 [Abstract] [Full Text]  
• Schuetze, S. M., Patel, S. (2009). Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?. The Oncologist 14: 1003-1012 [Abstract] [Full Text]  
• Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., Shamberger, R. C., Goorin, A., Miser, J., Meyer, J., Arndt, C. A.S., Sailer, S., Marcus, K., Perlman, E., Dickman, P., Grier, H. E. (2009). Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study. JCO 27: 2536-2541 [Abstract] [Full Text]  
• Scotlandi, K., Remondini, D., Castellani, G., Manara, M. C., Nardi, F., Cantiani, L., Francesconi, M., Mercuri, M., Caccuri, A. M., Serra, M., Knuutila, S., Picci, P. (2009). Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. JCO 27: 2209-2216 [Abstract] [Full Text]  
• Paulussen, M., Bielack, S., Jurgens, H., Casali, P. G., On behalf of the ESMO Guidelines Working Group, (2009). Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv140-iv142 [Full Text]  
• Kikuta, K., Tochigi, N., Shimoda, T., Yabe, H., Morioka, H., Toyama, Y., Hosono, A., Beppu, Y., Kawai, A., Hirohashi, S., Kondo, T. (2009). Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics. Clin. Cancer Res. 15: 2885-2894 [Abstract] [Full Text]  
• Beauchamp, E., Bulut, G., Abaan, O., Chen, K., Merchant, A., Matsui, W., Endo, Y., Rubin, J. S., Toretsky, J., Uren, A. (2009). GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein. J. Biol. Chem. 284: 9074-9082 [Abstract] [Full Text]  
• Dantonello, T. M., Int-Veen, C., Harms, D., Leuschner, I., Schmidt, B. F., Herbst, M., Juergens, H., Scheel-Walter, H.-G., Bielack, S. S., Klingebiel, T., Dickerhoff, R., Kirsch, S., Brecht, I., Schmelzle, R., Greulich, M., Gadner, H., Greiner, J., Marky, I., Treuner, J., Koscielniak, E. (2009). Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults. JCO 27: 1446-1455 [Abstract] [Full Text]  
• Sonobe, M., Bando, T., Date, H. (2009). Peripheral primitive neuroectodermal tumour of the chest wall invading lung with regional lymph node metastasis. Eur. J. Cardiothorac. Surg. 35: 185-187 [Abstract] [Full Text]  
• Lin, P. P., Pandey, M. K., Jin, F., Xiong, S., Deavers, M., Parant, J. M., Lozano, G. (2008). EWS-FLI1 Induces Developmental Abnormalities and Accelerates Sarcoma Formation in a Transgenic Mouse Model. Cancer Res. 68: 8968-8975 [Abstract] [Full Text]  
• Paulussen, M., Craft, A. W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Kohler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg, H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan, A., Jurgens, H. (2008). Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment--Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. JCO 26: 4385-4393 [Abstract] [Full Text]  
• Mackall, C. L., Rhee, E. H., Read, E. J., Khuu, H. M., Leitman, S. F., Bernstein, D., Tesso, M., Long, L. M., Grindler, D., Merino, M., Kopp, W., Tsokos, M., Berzofsky, J. A., Helman, L. J. (2008). A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. Clin. Cancer Res. 14: 4850-4858 [Abstract] [Full Text]  
• Rodriguez-Galindo, C., Navid, F., Liu, T., Billups, C. A., Rao, B. N., Krasin, M. J. (2008). Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol 19: 814-820 [Abstract] [Full Text]  
• Barry, E. V., Lipshultz, S. E., Sallan, S. E. (2008). Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention. Am Soc Clin Oncol Ed Book 2008: 448-453 [Abstract] [Full Text]  
• Bacci, G., Balladelli, A., Forni, C., Ferrari, S., Longhi, A., Benassi, M. S., Briccoli, A., Serra, M., Picci, P. (2007). Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 18: 2037-2040 [Abstract] [Full Text]  
• Skubitz, K. M., D'Adamo, D. R. (2007). Sarcoma. Mayo Clin Proc. 82: 1409-1432 [Abstract] [Full Text]  
• Bacci, G., Balladelli, A., Forni, C., Longhi, A., Serra, M., Fabbri, N., Alberghini, M., Ferrari, S., Benassi, M. S., Picci, P. (2007). Ewing's sarcoma family tumours: DIFFERENCES IN CLINICOPATHOLOGICAL CHARACTERISTICS AT PRESENTATION BETWEEN LOCALISED AND METASTATIC TUMOURS. J Bone Joint Surg Br 89-B: 1229-1233 [Abstract] [Full Text]  
• Wan, X., Helman, L. J. (2007). The Biology Behind mTOR Inhibition in Sarcoma. The Oncologist 12: 1007-1018 [Abstract] [Full Text]  
• Lissat, A., Vraetz, T., Tsokos, M., Klein, R., Braun, M., Koutelia, N., Fisch, P., Romero, M. E., Long, L., Noellke, P., Mackall, C. L., Niemeyer, C. M., Kontny, U. (2007). Interferon-{gamma} Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity. Am. J. Pathol. 170: 1917-1930 [Abstract] [Full Text]  
• Castex, M.-P., Rubie, H., Stevens, M. C.G., Escribano, C. C., de Gauzy, J. S., Gomez-Brouchet, A., Rey, A., Delattre, O., Oberlin, O. (2007). Extraosseous Localized Ewing Tumors: Improved Outcome With Anthracyclines--The French Society of Pediatric Oncology and International Society of Pediatric Oncology. JCO 25: 1176-1182 [Abstract] [Full Text]  
• Delloye, C., Banse, X., Brichard, B., Docquier, P.-L., Cornu, O. (2007). Pelvic Reconstruction with a Structural Pelvic Allograft After Resection of a Malignant Bone Tumor. JBJS 89: 579-587 [Abstract] [Full Text]  
• Pappo, A. S., Lyden, E., Breitfeld, P., Donaldson, S. S., Wiener, E., Parham, D., Crews, K. R., Houghton, P., Meyer, W. H. (2007). Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. JCO 25: 362-369 [Abstract] [Full Text]  
• Iwamoto, Y. (2007). Diagnosis and Treatment of Ewing's Sarcoma. Jpn J Clin Oncol 37: 79-89 [Abstract] [Full Text]  
• Bhatia, S., Krailo, M. D., Chen, Z., Burden, L., Askin, F. B., Dickman, P. S., Grier, H. E., Link, M. P., Meyers, P. A., Perlman, E. J., Rausen, A. R., Robison, L. L., Vietti, T. J., Miser, J. S. (2007). Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood 109: 46-51 [Abstract] [Full Text]  
• Yock, T. I., Krailo, M., Fryer, C. J., Donaldson, S. S., Miser, J. S., Chen, Z., Bernstein, M., Laurie, F., Gebhardt, Mark. C., Grier, H. E., Tarbell, N. J. (2006). Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091--A Report From the Children's Oncology Group. JCO 24: 3838-3843 [Abstract] [Full Text]  
• Toretsky, J. A., Erkizan, V., Levenson, A., Abaan, O. D., Parvin, J. D., Cripe, T. P., Rice, A. M., Lee, S. B., Uren, A. (2006). Oncoprotein EWS-FLI1 Activity Is Enhanced by RNA Helicase A. Cancer Res. 66: 5574-5581 [Abstract] [Full Text]  
• Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., Juergensg, H. (2006). Ewing's Sarcoma Family of Tumors: Current Management.. The Oncologist 11: 503-519 [Abstract] [Full Text]  
• Bernstein, M. L., Devidas, M., Lafreniere, D., Souid, A.-K., Meyers, P. A., Gebhardt, M., Stine, K., Nicholas, R., Perlman, E. J., Dubowy, R., Wainer, I. W., Dickman, P. S., Link, M. P., Goorin, A., Grier, H. E. (2006). Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--A Report From the Children's Oncology Group. JCO 24: 152-159 [Abstract] [Full Text]  
• Scurr, M., Judson, I. (2006). How to Treat the Ewing's Family of Sarcomas in Adult Patients. The Oncologist 11: 65-72 [Abstract] [Full Text]  
• Hawkins, D. S., Schuetze, S. M., Butrynski, J. E., Rajendran, J. G., Vernon, C. B., Conrad, E. U. III, Eary, J. F. (2005). [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors. JCO 23: 8828-8834 [Abstract] [Full Text]  
• Kondo, S., Yamaguchi, U., Sakurai, S., Ikezawa, Y., Chuman, H., Tateishi, U., Furuta, K., Hasegawa, T. (2005). Cytogenetic Confirmation of a Gastrointestinal Stromal Tumor and Ewing Sarcoma/Primitive Neuroectodermal Tumor in a Single Patient. Jpn J Clin Oncol 35: 753-756 [Abstract] [Full Text]  
• Hendershot, E. (2005). Treatment Approaches for Metastatic Ewing's Sarcoma: A Review of the Literature. Journal of Pediatric Oncology Nursing 22: 339-352 [Abstract]  
• Barker, L. M., Pendergrass, T. W., Sanders, J. E., Hawkins, D. S. (2005). Survival After Recurrence of Ewing's Sarcoma Family of Tumors. JCO 23: 4354-4362 [Abstract] [Full Text]  
• Marina, N., Meyers, P. A. (2005). High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission. JCO 23: 4262-4264 [Full Text]  
• Baker, L. H. (2005). Medical and Pediatric Oncology, Not Adult and Pediatric Oncology. JCO 23: 4003-4005 [Full Text]  
• Weber, K. L. (2005). What's New in Musculoskeletal Oncology. JBJS 87: 1400-1410 [Full Text]  
• Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., Garcia-Echeverria, C., Hofmann, F., Picci, P. (2005). Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Res. 65: 3868-3876 [Abstract] [Full Text]  
• Wright, J. G., Gebhardt, M. C. (2005). Multicenter Clinical Trials in Orthopaedics: Time for Musculoskeletal Specialty Societies to Take Action. JBJS 87: 214-217 [Full Text]  
• Weber, K. L. (2004). What's New in Musculoskeletal Oncology. JBJS 86: 1104-1109 [Full Text]  
• Fuchs, B., Inwards, C. Y., Janknecht, R. (2004). Vascular Endothelial Growth Factor Expression is Up-Regulated by EWS-ETS Oncoproteins and Sp1 and May Represent an Independent Predictor of Survival in Ewing's Sarcoma. Clin. Cancer Res. 10: 1344-1353 [Abstract] [Full Text]  
• (2003). Lucina. Arch. Dis. Child. 88: 744-744 [Full Text]  
• Goorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., Link, M. P. (2003). Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651. JCO 21: 1574-1580 [Abstract] [Full Text]  
• Wittes, R. E. (2003). Therapies for Cancer in Children -- Past Successes, Future Challenges. NEJM 348: 747-749 [Full Text]